Autologous Stem Cell Transplant for Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

November 30, 2012

Study Completion Date

June 30, 2016

Conditions
Multiple Sclerosis
Interventions
OTHER

immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT),

"Stem Cell Mobilization with Cyclophosphamide 4.5 gm/m2 and rhGCSF 10 ug/kg/d x 10 day.~Stem Cell Collection with Cobe Spectra Stem Cell Purification with Miltenyi CliniMACS Stem Cell Transplant Conditioning with Busulphan 9.6 mg/kg iv, Cyclophosphamide 200 mg/kg iv, rabbit ATG 5 mg/kg iv followed by CD34 selected autologous hematopoietic stem cell transplant"

OTHER

Standard Therapy

Patient will receive standard therapy as decided upon by their treating neurologist.

Trial Locations (1)

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

All Listed Sponsors
collaborator

Multiple Sclerosis Scientific Research Foundation

UNKNOWN

lead

Ottawa Hospital Research Institute

OTHER